Bolt Biotherapeutics Inc BOLT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EST
1.47quote price arrow up+0.02 (+1.38%)
Volume
121,066
52 week range
1.18 - 3.73
Loading...
  • Open1.45
  • Day High1.51
  • Day Low1.45
  • Prev Close1.45
  • 52 Week High3.73
  • 52 Week High Date02/03/22
  • 52 Week Low1.18
  • 52 Week Low Date12/28/22

Key Stats

  • Market Cap55.362M
  • Shares Out37.66M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change13.08

KEY STATS

  • Open1.45
  • Day High1.51
  • Day Low1.45
  • Prev Close1.45
  • 52 Week High3.73
  • 52 Week High Date02/03/22
  • 52 Week Low1.18
  • 52 Week Low Date12/28/22
  • Market Cap55.362M
  • Shares Out37.66M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change13.08

RATIOS/PROFITABILITY

  • EPS (TTM)-2.55
  • P/E (TTM)-0.58
  • Fwd P/E (NTM)-0.68
  • EBITDA (TTM)-94.709M
  • ROE (TTM)-41.12%
  • Revenue (TTM)4.826M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,973.85%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/30/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Bolt Biotherapeutics Inc

 

Profile

MORE
Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those...
Randall Schatzman Ph.D.
Chief Executive Officer, Director
William Quinn
Chief Financial Officer
Address
900 Chesapeake Drive
Redwood City, CA
94063
United States

Top Peers

SYMBOLLASTCHG%CHG
DYAI
Dyadic International Inc
1.79-0.07-3.76%
ARAV
Aravive Inc
1.99+0.17+9.34%
OCX
OncoCyte Corp
0.39+0.002+0.5155%
ONCT
Oncternal Therapeutics Inc
1.09-0.03-2.68%
BCLI
Brainstorm Cell Therapeutics Inc
2.70+0.60+28.57%